AU2003254447A1 - Treatment of proliferative disorders - Google Patents

Treatment of proliferative disorders

Info

Publication number
AU2003254447A1
AU2003254447A1 AU2003254447A AU2003254447A AU2003254447A1 AU 2003254447 A1 AU2003254447 A1 AU 2003254447A1 AU 2003254447 A AU2003254447 A AU 2003254447A AU 2003254447 A AU2003254447 A AU 2003254447A AU 2003254447 A1 AU2003254447 A1 AU 2003254447A1
Authority
AU
Australia
Prior art keywords
treatment
proliferative disorders
proliferative
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003254447A
Inventor
David Hugh BEACH
Hiroshi Kondoh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University College London
Original Assignee
University College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University College London filed Critical University College London
Publication of AU2003254447A1 publication Critical patent/AU2003254447A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003254447A 2002-07-11 2003-07-11 Treatment of proliferative disorders Abandoned AU2003254447A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0216097.6 2002-07-11
GB0216097A GB0216097D0 (en) 2002-07-11 2002-07-11 Treatment of proliferative disorders
PCT/GB2003/002993 WO2004007720A2 (en) 2002-07-11 2003-07-11 Treatment of proliferative disorders

Publications (1)

Publication Number Publication Date
AU2003254447A1 true AU2003254447A1 (en) 2004-02-02

Family

ID=9940259

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003254447A Abandoned AU2003254447A1 (en) 2002-07-11 2003-07-11 Treatment of proliferative disorders

Country Status (3)

Country Link
AU (1) AU2003254447A1 (en)
GB (1) GB0216097D0 (en)
WO (1) WO2004007720A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1595957A1 (en) * 2004-05-12 2005-11-16 Erich Eigenbrodt Phosphoglycerate mutases and enzyme products
US8563730B2 (en) 2008-05-16 2013-10-22 Takeda San Diego, Inc. Pyrazole and fused pyrazole glucokinase activators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413939B1 (en) * 1997-10-31 2002-07-02 The Picower Institute For Medical Research Inducible phosphofructokinase and the Warburg effect
WO2001068667A1 (en) * 2000-03-14 2001-09-20 The Johns Hopkins University School Of Medicine Arrest of proliferation of highly glycolytic tumors

Also Published As

Publication number Publication date
GB0216097D0 (en) 2002-08-21
WO2004007720A2 (en) 2004-01-22
WO2004007720A3 (en) 2004-04-22

Similar Documents

Publication Publication Date Title
AU2003286567A1 (en) Methods for the treatment of skin disorders
AU2003258305A1 (en) Combination therapy for treatment of fibrotic disorders
AU2003223380A1 (en) Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
AU2003249244A1 (en) Methods for the treatment of neoplasms
IL210090A0 (en) TREATMENT OF TNFa RELATED DISORDERS
AU2003259249A1 (en) Pyridazinylpiperazine derivatives for treating pain
AU2002257936A1 (en) Methods of well treatment
AU2003300791A1 (en) Combination therapy for the treatment of pain
AU2002334870B8 (en) Combinations for the treatment of immunoinflammatory disorders
AU2003228819A1 (en) Combinations for the treatment of inflammatory skin disorders
AU2003286728A1 (en) Compounds for the treatment of metabolic disorders
AU2003293099A1 (en) Treatment of dna damage related disorders
AU2003210730A1 (en) Azabicyclo-substituted benzoylamides and thioamides for treatment of cns-related disorders
AU2003219981A1 (en) Benzimidazole-derivatives for the treatment of sexual dysfunction
AU2003251875A1 (en) Combination therapy for the treatment of neoplasms
AU2003270536A1 (en) Method of treating skin disorders
AU2003251904A1 (en) Combinations of drugs for the treatment of neoplasms
AU2003223538A1 (en) Methods for the treatment of cancer
AU2003259833A1 (en) Methods of treating neurodegenerative diseases
AU2003266965A1 (en) Use of carboxamides for the treatment of tinnitus
AU2002258798A1 (en) Methods for the treatment of hepatic disorders
AU2003237460A1 (en) Combination treatments for purinoceptor-related disorders
AU2003254447A1 (en) Treatment of proliferative disorders
AU2003274885A1 (en) Phenyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain or gastrointestinal disorders
AU2003296242A1 (en) Thia-epothilone derivatives for the treatment of cancer

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase